206 related articles for article (PubMed ID: 35590003)
1. Reversible lysine-targeted probes reveal residence time-based kinase selectivity.
Yang T; Cuesta A; Wan X; Craven GB; Hirakawa B; Khamphavong P; May JR; Kath JC; Lapek JD; Niessen S; Burlingame AL; Carelli JD; Taunton J
Nat Chem Biol; 2022 Sep; 18(9):934-941. PubMed ID: 35590003
[TBL] [Abstract][Full Text] [Related]
2. Targeting protein kinases with selective and semipromiscuous covalent inhibitors.
Miller RM; Taunton J
Methods Enzymol; 2014; 548():93-116. PubMed ID: 25399643
[TBL] [Abstract][Full Text] [Related]
3. Cell-Active, Reversible, and Irreversible Covalent Inhibitors That Selectively Target the Catalytic Lysine of BCR-ABL Kinase.
Chen P; Sun J; Zhu C; Tang G; Wang W; Xu M; Xiang M; Zhang CJ; Zhang ZM; Gao L; Yao SQ
Angew Chem Int Ed Engl; 2022 Jun; 61(26):e202203878. PubMed ID: 35438229
[TBL] [Abstract][Full Text] [Related]
4. Assessing Lysine and Cysteine Reactivities for Designing Targeted Covalent Kinase Inhibitors.
Liu R; Yue Z; Tsai CC; Shen J
J Am Chem Soc; 2019 Apr; 141(16):6553-6560. PubMed ID: 30945531
[TBL] [Abstract][Full Text] [Related]
5. Selectively Targeting the Kinome-Conserved Lysine of PI3Kδ as a General Approach to Covalent Kinase Inhibition.
Dalton SE; Dittus L; Thomas DA; Convery MA; Nunes J; Bush JT; Evans JP; Werner T; Bantscheff M; Murphy JA; Campos S
J Am Chem Soc; 2018 Jan; 140(3):932-939. PubMed ID: 29232121
[TBL] [Abstract][Full Text] [Related]
6. Reactive Chemical Probes: Beyond the Kinase Cysteinome.
Jones LH
Angew Chem Int Ed Engl; 2018 Jul; 57(30):9220-9223. PubMed ID: 29644769
[TBL] [Abstract][Full Text] [Related]
7. Global Reactivity Profiling of the Catalytic Lysine in Human Kinome for Covalent Inhibitor Development.
Tang G; Wang W; Zhu C; Huang H; Chen P; Wang X; Xu M; Sun J; Zhang CJ; Xiao Q; Gao L; Zhang ZM; Yao SQ
Angew Chem Int Ed Engl; 2024 Mar; 63(12):e202316394. PubMed ID: 38248139
[TBL] [Abstract][Full Text] [Related]
8. The Cysteinome of Protein Kinases as a Target in Drug Development.
Chaikuad A; Koch P; Laufer SA; Knapp S
Angew Chem Int Ed Engl; 2018 Apr; 57(16):4372-4385. PubMed ID: 28994500
[TBL] [Abstract][Full Text] [Related]
9. Lysine-Targeted Inhibitors and Chemoproteomic Probes.
Cuesta A; Taunton J
Annu Rev Biochem; 2019 Jun; 88():365-381. PubMed ID: 30633551
[TBL] [Abstract][Full Text] [Related]
10. Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome.
Rao S; Gurbani D; Du G; Everley RA; Browne CM; Chaikuad A; Tan L; Schröder M; Gondi S; Ficarro SB; Sim T; Kim ND; Berberich MJ; Knapp S; Marto JA; Westover KD; Sorger PK; Gray NS
Cell Chem Biol; 2019 Jun; 26(6):818-829.e9. PubMed ID: 30982749
[TBL] [Abstract][Full Text] [Related]
11. Determining Cysteines Available for Covalent Inhibition Across the Human Kinome.
Zhao Z; Liu Q; Bliven S; Xie L; Bourne PE
J Med Chem; 2017 Apr; 60(7):2879-2889. PubMed ID: 28326775
[TBL] [Abstract][Full Text] [Related]
12. Selective targeting of distinct active site nucleophiles by irreversible SRC-family kinase inhibitors.
Gushwa NN; Kang S; Chen J; Taunton J
J Am Chem Soc; 2012 Dec; 134(50):20214-7. PubMed ID: 23190395
[TBL] [Abstract][Full Text] [Related]
13. Developing irreversible inhibitors of the protein kinase cysteinome.
Liu Q; Sabnis Y; Zhao Z; Zhang T; Buhrlage SJ; Jones LH; Gray NS
Chem Biol; 2013 Feb; 20(2):146-59. PubMed ID: 23438744
[TBL] [Abstract][Full Text] [Related]
14. Chemical genetic strategy for targeting protein kinases based on covalent complementarity.
Garske AL; Peters U; Cortesi AT; Perez JL; Shokat KM
Proc Natl Acad Sci U S A; 2011 Sep; 108(37):15046-52. PubMed ID: 21852571
[TBL] [Abstract][Full Text] [Related]
15. Broad-Spectrum Kinase Profiling in Live Cells with Lysine-Targeted Sulfonyl Fluoride Probes.
Zhao Q; Ouyang X; Wan X; Gajiwala KS; Kath JC; Jones LH; Burlingame AL; Taunton J
J Am Chem Soc; 2017 Jan; 139(2):680-685. PubMed ID: 28051857
[TBL] [Abstract][Full Text] [Related]
16. Covalent docking of large libraries for the discovery of chemical probes.
London N; Miller RM; Krishnan S; Uchida K; Irwin JJ; Eidam O; Gibold L; Cimermančič P; Bonnet R; Shoichet BK; Taunton J
Nat Chem Biol; 2014 Dec; 10(12):1066-72. PubMed ID: 25344815
[TBL] [Abstract][Full Text] [Related]
17. Strategic Design of Catalytic Lysine-Targeting Reversible Covalent BCR-ABL Inhibitors*.
Quach D; Tang G; Anantharajan J; Baburajendran N; Poulsen A; Wee JLK; Retna P; Li R; Liu B; Tee DHY; Kwek PZ; Joy JK; Yang WQ; Zhang CJ; Foo K; Keller TH; Yao SQ
Angew Chem Int Ed Engl; 2021 Jul; 60(31):17131-17137. PubMed ID: 34008286
[TBL] [Abstract][Full Text] [Related]
18. Multitarget inhibitors/probes that target LRRK2 and AURORA A kinases noncovalently and covalently.
Wang W; Wang X; Tang G; Zhu C; Xiang M; Xiao Q; Zhang ZM; Gao L; Yao SQ
Chem Commun (Camb); 2023 Sep; 59(72):10789-10792. PubMed ID: 37594149
[TBL] [Abstract][Full Text] [Related]
19. Design of reversible, cysteine-targeted Michael acceptors guided by kinetic and computational analysis.
Krishnan S; Miller RM; Tian B; Mullins RD; Jacobson MP; Taunton J
J Am Chem Soc; 2014 Sep; 136(36):12624-30. PubMed ID: 25153195
[TBL] [Abstract][Full Text] [Related]
20. Construction of Covalent Bisubstrate Inhibitor of Protein Kinase Reacting with Cysteine Residue at Substrate-Binding Site.
Sõrmus T; Lavogina D; Teearu A; Enkvist E; Uri A; Viht K
J Med Chem; 2022 Aug; 65(16):10975-10991. PubMed ID: 35960538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
